Considerations related to PEP regimens Currently recommended regimens for PEP are safe and have limited side-effects. Hepatitis B is not a contraindication for offering PEP regimens that include TDF, FTC or 3TC, and so assessing for and ruling out hepatitis B infection should not be a precondition for offering PEP. Hepatitis B virus tests are not available everywhere and particularly scarce in community settings. However, if the test is available and particularly in settings where hepatitis B is hyperendemic, people started on PEP should be tested for hepatitis B to detect active infection and the need for treatment. Results of hepatitis B testing have no relevance to PEP prescribing decisions. People with active HBV infection should be monitored for a flare of hepatitis after discontinuation of TDF-, 3TC- or FTCbased PEP if these drugs are not continued for the treatment of HBV. This may require referral to a hepatologist. Hepatitis flares are extremely rare. Choice of an HIV PEP regimen should consider the ARV drugs already being procured within national HIV programmes. Additional considerations include the availability of heatstable formulations, daily dosing, availability and affordability.